EGFR and lung cancer: A phase II multicenter, open‐label, single‐arm trial has been initiated to evaluate the efficacy and safety of afatinib and bevacizumab combination as salvage therapy for EGFR‐mutated lung cancer in patients previously treated with osimertinib.